SAMβA (TFA)

SAMβA TFA is conjugated to the cell permeable peptide TAT47-57. SAMβA TFA, a rationally designed selective antagonist of Mfn1-βIIPKC association. SAMβA TFA is a selective inhibitor of mitofusin 1-βIIPKC association improves heart failure outcome in rats[1].

Product Specifications

UNSPSC

12352209

Target

PKC

Type

Peptides

Related Pathways

Epigenetics; TGF-beta/Smad

Applications

Neuroscience-Neuromodulation

Field of Research

Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/samβa-tfa.html

Purity

99.13

Solubility

H2O : 50 mg/mL (ultrasonic)

Smiles

OC(C(F)(F)F)=O.OC([C@@H](NC([C@@H](NC([C@@H](NC([C@H](CC1=CC=CC=C1)NC([C@@H](NC([C@@H](NC([C@@H](NC([C@@H](NC([C@H](CCCNC(N)=N)N)=O)CC(N)=O)=O)C)=O)CCC(O)=O)=O)CC(N)=O)=O)=O)CC(O)=O)=O)CCCNC(N)=N)=O)CC2=CC=CC=C2)=O.[x]

Molecular Formula

C50H73N17O16.xC2HF3O2

Molecular Weight

1168.22 (free acid)

References & Citations

[1]Julio C B Ferreira A selective inhibitor of mitofusin 1-βIIPKC association improves heart failure outcome in rats. Nat Commun. 2019 Jan 18;10 (1) :329.